Scandinavian Biopharma has been awarded 7.4 million EUR from the EU for clinical trials of ETVAX® – a unique and newly developed vaccine against diarrheal disease

In international competition Scandinavian Biopharma has been awarded a grant of 7,4 million Euro for clinical trials of the ETEC vaccine ETVAX®.  The clinical trials will be conducted in the African countries Zambia and The Gambia. The newly developed vaccine ETVAX® targets diarrhea caused by ETEC – an enteric bacteria responsible for hundred thousands of […]